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Excessive hyperplastic cell growth within occlusive vascular lesions has been recognized as a key component of the inflammatory response
associated with atherosclerosis, restenosis post-angioplasty, and graft atherosclerosis after coronary artery bypass. Understanding the
molecular mechanisms that regulate arterial cell proliferation is therefore essential for the development of new tools for the treatment
of these diseases. Mammalian cell proliferation is controlled by a large number of proteins that modulate the mitotic cell cycle, including
cyclin-dependent kinases, cyclins, and tumour suppressors. The purpose of this review is to summarize current knowledge about the
role of these cell cycle regulators in the development of native and graft atherosclerosis that has arisen from animal studies, histological
examination of specimens from human patients, and genetic studies.
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This article is part of the Spotlight Issue on: Mechanisms of Vascular Inflammation
1. Introduction
Atherosclerosis, restenosis (vessel renarrowing after successful
angioplasty), and graft atherosclerosis after coronary artery
bypass surgery are chronic inflammatory diseases that lead to
the formation of obstructive vascular lesions. Excessive cell pro-
liferation within the arterial wall is a key contributor to plaque
growth; therefore, understanding the molecular mechanisms that
control hyperplastic growth of vascular cells is of utmost impor-
tance for the development of efficient therapies against athero-
sclerosis and restenosis.
Mammalian cell proliferation is controlled by a large number of
proteins that modulate the mitotic cell cycle (Figure 1). Pro-
gression through the cell cycle requires the activation of holoen-
zymes composed of a catalytic cyclin-dependent protein kinase
(CDK) and the regulatory subunit cyclin. Specific CDKs are
sequentially activated during different phases of the cell cycle by
the oscillating synthesis and degradation of their cyclin partners.
The activity of CDK/cyclins is also regulated by phosphoryl-
ation/dephosphorylation cycles and by their interaction with
CDK inhibitory proteins (CKIs) of the Cip/Kip (CDK interacting
protein/kinase inhibitory protein: p21Cip1, p27Kip1, p57Kip2) and
Ink4 (inhibitor of CDK4: p16Ink4a, p15Ink4b, p18Ink4c, p19Ink4d)
families.1 All Cip/Kip proteins bind to and inhibit a wide spectrum
of CDK/cyclin complexes, while the Ink4 proteins specifically
inhibit cyclin D-associated CDKs. Mitogenic and antimitogenic
stimuli affect the rates of CKI synthesis and degradation, as well
as their redistribution among different CDK/cyclin heterodimers.
In addition, other proteins, such as the transcriptional regulator
p53, modulate the expression and function of CKIs to ensure
that cells do not progress to the next phase of the cell cycle
before appropriate conditions have been reached. CDK/cyclin
activity modulates E2F/DP- and retinoblastoma protein
(Rb)-dependent transcription of target genes involved in cell
cycle control and DNA biosynthesis (Figure 2). In non-proliferating
cells, lack of CDK/cyclin activity leads to the accumulation of
hypophosphorylated Rb, which binds to and inactivates the
dimeric transcription factor E2F/DP. In proliferating cells, CDK/
cyclin activation causes the accumulation of hyperphosphorylated
Rb during late G1-phase, thus causing the release of E2F/DP and
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the transactivation of various target genes necessary for cell cycle
progression.
Cellular proliferation within atherosclerotic and restenotic
plaques has been predominantly observed in vascular smooth
muscle cells (VSMCs) and macrophages. Animal studies and
tissue culture experiments have demonstrated that several cardio-
vascular risk factors promote the proliferation of these cell
types,2 –4 and there is evidence that these risk factors affect the
expression or activity of CDK/cyclins and CKIs. For example, the
mitogenic effects of oxLDL and homocysteine on VSMCs have
been associated with higher expression of several cyclins and
increased activity of CDKs.5,6 Similarly, angiotensin II treatment
increases cyclin D1 and CDK4 expression and decreases p21Cip1
and p27Kip1 levels in rat mesenteric arteries.7 This review discusses
animal and human studies that examine the role of cell cycle
regulators in native and graft atherosclerosis. Although these pro-
teins also play an important role in restenosis post-angioplasty, this
is beyond the objectives of this article and is reviewed
elsewhere.8,9
2. Cell cycle regulators in
experimental atherosclerosis
This section reviews animal studies assessing the role in athero-
sclerosis of various proteins involved in cell cycle regulation,
including the transcriptional regulators p53 and Rb, and the Cip/
Kip family members p27Kip1 and p21Cip1 (summarized in Table 1).
To date, no animal model studies have been reported on the
role in atherosclerosis of p57Kip2, p15INK4b, p16INK4a, p18INK4c
and p19INK4d. However, such studies appear warranted, given the
recent genome-wide association studies suggesting a role for the
INK4/ARF locus in the development of coronary artery disease
(CAD) and myocardial infarction (MI) (see below).
2.1 p53
The tumour suppressor p53 mediates the cellular response to a
variety of stresses mainly by regulating the transcription of over
150 genes.10 Active p53 can induce reversible growth arrest in
the G1 or G2 phases of the cell cycle, as well as cellular senes-
cence or apoptosis. The first evidence supporting a role for p53
in the development of atherosclerosis was reported by Guevara
et al.,11 who demonstrated that p53 deficiency accelerates ather-
oma development in the aorta of apolipoprotein E (apoE)-null
mice, coinciding with increased cell proliferation within the ather-
oma. Later, Mercer et al.12 confirmed the enhanced aortic athero-
sclerosis of mice doubly deficient for p53 and apoE compared with
apoE-null controls. However, in this latter study, p53 deficiency did
not significantly increase atheroma development in the brachioce-
phalic artery, suggesting that the atheroprotective actions of p53
depends on the vascular bed being examined. Lesions in the bra-
chiocephalic artery of p53-deficient animals contained an increased
proportion of proliferating cells and reduced numbers of apoptotic
Figure 1 Mammalian cell cycle regulation by CDK/cyclin holoenzymes and CKIs. The cell cycle consists of four distinct phases: G1, S (DNA
replication), G2, and M (mitosis). Activation of specific CDK/cyclin complexes drives progression through these cell cycle phases. CKIs of the
Cip/kip and the INK4 families interact with and inactivate CDK/cyclin holoenzymes, thereby blocking cell cycle progression and cell
proliferation.
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cells. Apoptosis within the atheroma affected both macrophages
and VSMC, whereas most proliferating cells were monocytes/
macrophages.12
The role of p53 in atherosclerosis development has also been
assessed by using bone marrow transplantation (BMT) strategies
to selectively inactivate p53 in haematopoietic cells. Van Vlijmen
et al.13 reported that lethally irradiated apoE*3-Leiden mice trans-
planted with p53-deficient bone marrow show a significant
increase in aortic atherosclerosis compared with mice transplanted
with p53-wild-type marrow. This finding coincided with a non-
significant tendency towards decreased apoptosis in mice receiving
p53-deficient marrow, and the authors suggested this to be the
mechanism underlying their findings. In contrast to previous
studies of the effect of global inactivation of p53,11,12 cell prolifer-
ation within the atheroma was not affected by p53-deficient
BMT.13 Merched et al.14 used a similar approach to analyse the
effect of p53 haematopoietic inactivation on atheroma develop-
ment in LDLR-null mice, another widely used model of athero-
sclerosis. These authors found that mice receiving p53-deficient
BMT develop significantly larger aortic atheromas than mice trans-
planted with p53-wild-type bone marrow. However, in contrast to
the results of Van Vlijmen et al.,13 p53-deficient BMT was associ-
ated with exacerbated cell proliferation within the atheroma.14
Using a different approach, Mercer et al.12 found that transplan-
tation of p53 wild-type bone marrow into p53-deficient apoE-null
mice reduced aortic plaque formation and neointimal cell prolifer-
ation in brachiocephalic arteries, but also markedly reduced apop-
tosis. Very recently, Boesten et al.15 showed that atherosclerosis
development in the aortic root, aortic arch, and thoracic aorta
of fat-fed apoE-null mice is unaffected by Cre-loxP-mediated
macrophage-selective inactivation of p53. Cell proliferation within
the atheroma was also unaffected by macrophage-specific p53
deficiency, whereas plaque apoptosis was markedly reduced.
Therefore, while most studies suggest an atheroprotective role
for p53, it is unclear whether this is achieved mainly through
effects on cell proliferation or apoptosis. The conflicting data
among studies might result from experimental differences; for
example, type of diet, periods of fat-feeding, and use of animal
models with different genetic modifications. Alternatively, they
might reflect cell-type-specific effects of p53, since p53-deficient
peritoneal macrophages exhibit reduced apoptosis under standard
culture conditions, whereas p53-deficient VSMCs exhibit increased
apoptosis.12 In this regard, it should be noted that adenovirus-
mediated overexpression of p53 induces VSMC apoptosis in a
collar model of murine atherosclerosis, suggesting that the antia-
poptotic actions of p53 in VSMCs in culture might not occur in
the atherosclerotic plaque.16 Another possible explanation is the
different technologies used to achieve tissue-specific p53 inacti-
vation, since BMT yields gene inactivation in both lymphoid and
myeloid haematopoietic lineages, while the Cre-LoxP technology
used by Boesten et al.15 inactivates the target gene only in
myeloid cells. Moreover, BMT might also provoke gene inactivation
in a subset of VSMCs and endothelial cells (ECs), since bone
marrow progenitors can also differentiate into these cell
types.17–19
Although the underlying mechanism of p53’s atheroprotective
action remains undefined, strategies to increase its expression or
function might be predicted to inhibit atherosclerosis. However,
p53 gain-of-function studies performed in our laboratory appear
to challenge this possibility, since atherosclerosis is unaffected in
Figure 2 Cell cycle control by E2F/DP and Rb. In G1, in the presence of low level of CKIs, active CDK/cyclin complexes trigger the hyper-
phosphorylation of Rb, releasing the dimeric transcription factor E2F/DP and thereby inducing the transactivation of genes with functional
E2F-binding sites (for example, growth and cell cycle regulators and genes encoding proteins required for nucleotide and DNA biosynthesis).
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apoE-null mice carrying an additional p53 allele that reproduces
the normal expression and regulation of the endogenous p53
gene (apoE-null Super-p53 mice).20 In this study, increased p53
function did not provoke significant differences in the size of ather-
osclerotic lesions within the ascending aorta, aortic arch, or thor-
acic aorta, irrespective of feeding with a high-fat diet or standard
chow. Cell proliferation and apoptosis within the atheroma were
similarly unaffected. These findings demonstrate that moderate
p53 gain-of-function does not limit atheroma development in
mice, and thus shed doubt on the utility of p53 activation as a
means of preventing atherosclerosis. However, it remains possible
that more intense increases in p53 function might have therapeutic
potential.
2.2 Retinoblastoma protein
Rb plays a major role in cell proliferation and apoptosis.21 It is well
established that hypophosphorylated Rb induces cell cycle arrest in
G1 by two mechanisms: first, it impedes E2F-mediated transcrip-
tion of genes involved in cell cycle progression (Figure 2), and sec-
ondly it actively represses transcription through the formation of
the Rb-E2F transcription repressor complex. The role of Rb in
the regulation of apoptosis was identified in loss-of-function
studies, showing that Rb deficiency in mice triggers p53-dependent
apoptosis21 and results in embryonic lethality.22
The effects of Rb disruption on atherogenesis have been
studied in apoE-null mice with selective inactivation of Rb in
macrophages (macrophage-Rbdel apoE-null mice).23 These
animals develop larger and more advanced aortic atheromas
than apoE-null mice, with a decreased macrophage content and
an increased percentage of VSMCs. Apoptosis within the ather-
oma is almost undistinguishable between the two groups,
indicating that macrophage Rb plays a minor role in cell-death
within the atheroma. In contrast, the authors found a significant
increase (2.6-fold) in lesional macrophage proliferation in
macrophage-Rbdel apoE-null mice, suggesting that inhibition of
macrophage proliferation is the major mechanism underlying
the atheroprotective properties of Rb. Since Rb also modulates
VSMC proliferation, senescence, and apoptosis,24 future studies
are warranted to investigate the effects on atherosclerosis devel-
opment of selective Rb inactivation in VSMCs.
2.3 p27Kip1
The Cip/Kip family member p27Kip1 is a CKI that plays a major role
in the control of the mammalian cell cycle in various pathophysio-
logical settings.25 p27Kip1 is maximally translated and stable in
quiescent cells, and contributes to growth arrest through the inhi-
bition of cyclin-CDK complexes. Upon mitogenic stimulation,
p27Kip1 is rapidly downregulated, allowing activation of cyclin E–
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Atherosclerosis development after genetic manipulation of cell-cycle regulators in the mouse
Mouse model Genetic modification Effect on atheroma
size
Effect on cell
proliferation
Effect on apoptosis Reference
apoE-null p53 global inactivation Increase Increase None Guevara et al.11
apoE-null p53 global inactivation Increase (aorta); none
(brachiocephalic)
Increase (brachiocephalic) Reduction
(brachiocephalic)
Mercer et al.12
apoE-null p53þ/þ BMT in p532/2
mice
Reduction (aorta); none
(brachiocephalic)
Reduction
(brachiocephalic)
Reduction
(brachiocephalic)
Mercer et al.12
apoE-null Macrophage-specific p53
deficiency
None None Reduction Boesten et al.15
apoE*3-Leiden p532/2 BMT in p53þ/þ
mice
Increase None None van Vlijmen et al.13
LDLR-null p532/2 BMT in p53þ/þ
mice
Increase Increase None Merched et al.14
apoE-null One extra p53 allele
(normally regulated)
None None None Sanz-Gonza´lez
et al.20
apoE-null Macrophage-specific Rb
deficiency
Increase Increase None Boesten et al.23
apoE-null p27Kip1 global inactivation Increase Increase Not studied Dı´ez-Juan and
Andre´s28
apoE-null p27Kip12/2 BMT in
p27Kip1þ/þ mice
Increase Increase Not studied Dı´ez-Juan et al.29
apoE-null p27Kip1 T187A mutation None None None Sanz-Gonza´lez
et al.40
apoE-null p21Cip1 global inactivation Reduction None Increase Merched and Chan42
apoE-null p21Cip12/2 BMT in
p21Cip1þ/þ mice
Reduction Not studied Increase Merched and Chan42
apoE-null p21Cip1 global inactivation Increase Not studied Not studied Khanna44
BMT, bone marrow transplant.
Only studies reporting statistically significant effects are included.
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CDK2 and cyclin A–CDK2 complexes and the subsequent tran-
scriptional activation of genes required for the G1/S transition
and the initiation of DNA replication.25,26
p27 acts as a tumour suppressor.27 Mouse studies performed
in our laboratory revealed that it also has atheroprotective
functions. We first showed that genetic inactivation of p27Kip1
greatly accelerates diet-induced atherogenesis in apoE-null mice
(6-fold), coinciding with enhanced proliferation of macrophages
and VSMCs within the atheroma (4-fold).28 Moreover, analysis
of apoE-null mice with one p27Kip1 allele inactivated revealed
that a moderate decrease in p27Kip1 protein expression is sufficient
to hasten atherosclerosis development in this model. In a sub-
sequent study, we demonstrated that haematopoietic cell-selective
disruption of p27Kip1 in apoE-null mice enhances arterial
macrophage proliferation and accelerates aortic atherosclerosis.29
Interestingly, this strategy also augmented aortic expression of
the proinflamatory cytokines CCL2/MCP-1 and CCL5/RANTES,
suggesting that p27Kip1 might have proliferation-independent
functions that affect the inflammatory response within the
atheroma. In this regard, in addition to modulating proliferation,
p27Kip1 regulates other cellular processes that may contribute to
the atherosclerosis development, such as migration, apoptosis,
and autophagy.30–37 Moreover, p27Kip1 interacts with a number
of proteins that might influence atheroma development, such
as the small GTPases RhoA31 and Rac36 and the signalling
adaptor Grb2.38,39 It remains to be demonstrated whether these
proliferation-independent functions and/or interactions with
signalling proteins contribute to the atheroprotective properties
of p27Kip1.
The molecular mechanisms that regulate p27 expression and
function in the arterial wall remain ill defined. It is well established
that p27Kip1 protein levels are mainly regulated by post-
translational modifications. One of the most consistently demon-
strated modifications of p27Kip1 is its phosphorylation at threonine
187 (T187), which is required for the degradation of p27Kip1 at the
G1/S transition and in the G2 phase prior to mitosis.26 To investi-
gate whether this post-translational modification of p27Kip1 plays a
role in atherosclerosis, our laboratory generated apoE-null mice
with both p27Kip1 alleles replaced by a version carrying a T!A
mutation at position 187 to block phosphorylation at this
residue (apoE-null p27T187A mice).40 We found that aortic
p27Kip1 expression was unaffected by the T187A mutation, and
atheroma size, lesion cellularity, cell proliferation, and apoptosis
were undistinguishable between fat-fed apoE-null p27T187A and
apoE-null mice. Hence, it can be concluded that phosphorylation
of p27Kip1 at T187 is not implicated in the control of aortic
p27Kip1 expression and atherosclerosis in hypercholesterolemic
mice. Future studies are therefore warranted to analyse the
effect of additional post-translational modifications of p27Kip1 on
atherosclerosis development.
2.4 p21Cip1
The Cip/Kip family member p21Cip1 is a major downstream target
of p53 that modulates cell proliferation. Global inactivation of
p21Cip1 reduces atherosclerosis burden in apoE-null mice fed
either standard chow or a proatherogenic high-fat diet.41,42
Moreover, transplantation of p21Cip1-deficient bone marrow into
apoE-null mice also reduces atheroma size, thus demonstrating a
protective effect of p21Cip1-deficiency in macrophages. This con-
trasts with studies on p53, p27Kip1, and Rb, whose total or
partial inactivation in mice aggravates atherosclerosis (see above).
In vivo incorporation of bromodeoxyuridine (BrdU) into
20-week-old apoE-null mice fed a normal chow diet revealed no
differences in lesional cell proliferation between p21Cip1-deficient
and p21Cip1-wild-type mice, suggesting that the atherogenic
actions of p21 are unrelated to its role as a cell cycle regulator.
However, cell proliferation in the atherosclerotic plaque probably
occurs at specific stages of lesion formation; so additional studies,
with mice at different ages and fed with high fat for different
periods, are required to precisely establish the consequences of
p21Cip1 inactivation on lesional cell proliferation. Merched and
Chan42 found significant upregulation of other growth suppressors
upon inactivation of p21Cip1, such as p16Ink4a, Rb, and p53, and
suggested that this might compensate the effect of p21Cip1
deficiency on cell proliferation. Specifically, the authors hypoth-
esize that the increased levels of p16Ink4a, a strong inhibitor of
CDK4, would displace other Cip/Kip family members (p27Kip1
and p57Kip2) from CDK4-cyclin D inhibitory complexes, making
them available to inhibit CDK2 and thereby decelerating cell
cycle progression and proliferation in the absence of p21Cip1.
Consistent with the previously reported antiapoptotic role of
p21Cip1, 43 Merched and Chan42 found increased lesion apoptosis
after both global and macrophage-specific inactivation of p21Cip1
(1.8- and 3-fold, respectively). Moreover, gene expression profiling
of thioglycolate-elicited peritoneal macrophages from p21Cip1-null
mice revealed higher expression of putative atheroprotective
factors (SR-BI, macrophage scavenger receptor A, and
LDL-receptor related protein) and lower levels of proinflamma-
tory molecules (macrophage inflammatory proteins 1 and 2 and
interleukin-1a). p21Cip1-deficient macrophages also exhibited a
2-fold increased phagocytic activity towards fluorescent latex
microspheres and apoptotic thymocytes. In summary, Merched
and Chan’s42 work demonstrates that p21Cip1 is a proatherogenic
molecule, since its inactivation limits the production of proinflam-
matory cytokines, enhances immune cell apoptosis, and upregu-
lates phagocytic macrophage activity, which facilitates apoptotic
cell clearance and prevents necrosis, thereby promoting plaque
stability.
Merched and Chan’s42 conclusions contrast with a very recent
study that reports that inactivation of p21Cip1 renders mice more
susceptible to high fat diet-induced atherosclerosis.44 However,
in this second study, the dietary fat level was only moderate, and
the mice used were on a mixed genetic background (FVB), had
low plasma lipid levels (maximum 100 mg/dL), and did not
readily develop atherosclerosis. Moreover, atheroma development
was analysed only in the coronary artery. In contrast, Merched and
Chan42 validated their data through the use of two dietary regi-
mens (regular chow and western diet), the study of global and
macrophage-restricted ablation of p21Cip1 in a widely used
mouse model of atherosclerosis (apoE-null mice), and analysis of
atherosclerosis lesions in whole aortas and in cross-sections of
the aortic sinus.
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3. Cell cycle regulators in
experimental graft atherosclerosis
Excessive cell proliferation and neointimal hyperplasia followed by
atheromatous plaque development are common features of both
vein graft and cardiac allograft atherosclerosis. In this section, we
discuss different cell cycle-based strategies employed to inhibit
experimental graft atherosclerosis (summarized in Table 2). We
also discuss several animal studies that highlight the important
role of the p53-p21Cip1 axis in this pathology.
3.1 Antisense oligodeoxynucleotides
(ODNs) targeting cell cycle regulators
The use of complementary oligodeoxynucleotides (ODNs) to
target CDK mRNAs and transcription factors involved in cell
cycle regulation has been mainly investigated in experimental
graft atherosclerosis. Mann et al.45,46 demonstrated the beneficial
effects of selectively blocking the expression of the cell cycle reg-
ulators CDK1 (also called CDC2) and proliferating cell nuclear
antigen (PCNA) in rabbit jugular veins grafted into carotid arteries.
These engineered grafts underwent a phenotypic shift from hyper-
plasia towards hypertrophy, maintained a normal endothelial phe-
notype, and were resistant to diet-induced atherosclerosis. The
benefits of this strategy have been confirmed by cotransfection
of antisense ODNs to PCNA and CDK1 in a rat cardiac allograft
model.47 Moreover, transfection of antisense ODNs to PCNA
alone significantly inhibits intimal hyperplasia in experimental
rabbit vein grafts,48 while transfection of antisense ODNs to
CDK1 alone has protective effects in a mouse coronary allograft
model.49 Increased expression of CDK1 has been detected in
the coronary arteries of chronically rejected allografts of non-
human primates,50 suggesting that this kinase is a key player in
graft vasculopathies and a potential target for gene therapy.
Another target of potential therapeutic interest is CDK2, since
enhanced CDK2 mRNA expression has been found in the
thickened intima of coronary arteries of mouse heterotopic
cardiac allografts, and antisense CDK2 ODNs efficiently inhibit
neointima formation and VCAM-1 expression in this disease
model.51
Antisense strategies have also targeted several ‘immediate-early’
genes implicated in vascular cell proliferation. Suggs et al.52
reported increased expression of c-fos and c-jun after perfusion
of rat vein grafts, and showed that treatment of grafts with anti-
sense ODNs to these ‘immediate-early’ genes significantly
reduced the thickness of the intimal layer in the perianastomotic
and midgraft regions. Similarly, expression of the c-myc oncopro-
tein has been correlated with VSMC proliferation during the
period of maximal intimal thickening in rat experimental vein
grafts,53 and intraoperative application of antisense c-myc oligo-
mers has been reported to inhibit neointima formation in a
porcine vein graft model.54,55 Similar protective effects on intimal
hyperplasia have been demonstrated for locally delivered antisense
ODNs to the proto-oncogene c-myb in rabbit experimental vein
grafts.56
3.2 Decoy ODNs targeting cell cycle
regulators
Other genetic approaches have used double-stranded ODNs
encoding the consensus-binding sequences for transcription
factors involved in the activation of atherogenic genes (‘decoy oli-
gonucleotides’). Treatment of experimental grafts with decoy
ODNs for E2F has been extensively explored, and has provided
strong evidence of reduced neointimal hyperplasia in mouse and
non-human primate cardiac allografts57–59 and in rabbit60,61 and
canine62 vein grafts. In these studies, E2F blockade correlated
with VSMC growth arrest and suppression of positive cell cycle
regulatory genes in the graft wall, and also with downregulation
of inflammatory mediators such as NFkappaB58 and E-selectin,59
without inhibiting endothelial repopulation after vein bypass.61
Moreover, in the setting of diet-induced hypercholesterolaemia,
delivery of E2F decoy ODNs provides vein grafts with long-term
resistance to atherosclerosis.60 Chimeric decoy ODNs, inhibiting
both E2F and NFkappaB, reduced intimal hyperplasia and acceler-
ated re-endothelialization in a rabbit model of vein graft, and these
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Reduction of neointimal thickening by antiproliferative gene therapy in animal models of graft vasculopathy
Strategy Target gene Animal model of graft atherosclerosis Reference
Antisense ODNs CDC2/PCNA Rabbit vein graft Mann et al.45,46
CDC2/PCNA Rat cardiac allograft Miniati et al.47
CDC2 Mouse cardiac allograft Isobe et al.49
PCNA Rabbit vein graft Fulton et al.48
CDK2 Mouse cardiac allograft Suzuki et al.51
c-fos/c-jun Rat vein graft Suggs et al.52
c-myc Porcine vein graft Mannion et al.54,55
c-myb Rabbit vein graft Fulton et al.56
‘Decoy’ ODNs E2F Mouse cardiac allograft Kawauchi et al.57 and Suzuki et al.59
E2F Primate cardiac allograft Kawauchi et al.57,58
E2F Rabbit vein graft Ehsan et al.60,61
E2F Canine vein graft Cho et al.62
E2F/NFkB chimera Rabbit vein graft Miyake et al.63
Overexpression growth suppressors p21Cip1 Rabbit vein graft Bai et al.70
p53 Porcine vein graft Wan et al.66
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effects correlated with reduced accumulation of VSMCs and
macrophages and with decreased expression of PDGF, VCAM-1,
and MCP1.63 Although it is beyond the scope of this review, it is
worth noting that the E2F decoy strategy (edifoligide) has been
explored in a series of clinical trials known as the PRoject of Ex
vivo Vein graft ENgineering via Transfection (PREVENT). While
confirming the safety and viability of E2F decoy ODNs treatments,
the four trials conducted to date have found that this treatment
was clinically ineffective at preventing human graft failure (reviewed
in64).
3.3 The p53-p21Cip1 axis in experimental
graft atherosclerosis
Several studies have highlighted the role of p53 and its target
p21Cip1 in experimental graft atherosclerosis. Neointimal hyperpla-
sia of vein grafts is significantly increased in p53-null mice,
coinciding with significantly reduced apoptosis, and augmented
and reduced lesional content of VSMCs and macrophages, respect-
ively.65 Moreover, cultured VSMCs exhibit increased proliferation
and migration and decreased apoptosis in response to sodium
nitroprusside, thus suggesting that p53 deficiency accelerates
neointima formation by promoting VSMC proliferation and abro-
gating cell apoptosis.65 In line with these findings, adenovirus-
mediated p53 overexpression significantly upregulates apoptosis
and reduces neointimal proliferation in porcine vein grafts,
thereby limiting neointimal thickening.66
In a rat model of vein arterialization, p21Cip1 is gradually down-
regulated, reaching a minimum by day 7 that is sustained until day
90, suggesting that reduced p21Cip1 levels may contribute to vascu-
lar cell proliferation in this pathological model.67 Although the
same study revealed no changes in p27Kip1 and p16INK4a
expression, further studies are required in other graft models to
conclusively address the role of CKIs in graft atherosclerosis,
since regulation of these proteins appears to vary depending on
the vascular bed.68,69 Interestingly, overexpression of p21Cip1 in
rabbit vein grafts by intraoperative transfection not only signifi-
cantly inhibits neointima formation but also induces maturation
of VSMCs from the neonatal to the adult phenotype.70 Addition-
ally, oral administration of the antiallergic drug tranilast in murine
cardiac transplantation models inhibits cardiac allograft vasculopa-
thy in association with increased neointimal expression of p21Cip1
and decreased expression of PCNA.71,72
4. Cell cycle regulators in human
atherosclerosis
The importance of proliferation in the growth of atherosclerotic
plaques has been extensively studied in human vascular obstructive
lesions. In this section, we summarize several reports that analyse
cell proliferation and the expression and localization of cell cycle
regulators within human atherosclerotic plaques.
4.1 Cell proliferation in human
atherosclerosis
The occurrence of cell proliferation in human vascular obstructive
disease is demonstrated by the consistent finding of proliferation
markers in human primary atheromatous plaques and restenotic
lesions.73– 83 However, it should be noted that some studies
have reported very low proliferation rates,73,74,76,78,80,82 while
others find high proliferative activity75,81,83 in human atherosclero-
sic and restenosic lesions. Several factors may contribute to these
conflicting findings, including technical issues (differences in tissue
fixatives, antigen accessibility, analysis of different proliferation
markers, etc.), differences in the arteries being analysed (for
example, peripheral, coronary, and carotid arteries), and variation
in the state of development of the atheroma (for example, fatty
streaks, fibrolipid plaques, or complicated atheromas). Supporting
this last possibility, complicated atheromas in human carotid
artery samples (type VI) have recently been reported to exhibit
higher proliferation rates than non-complicated fibrous lesions
(type V).84
Proliferating cells within human atherosclerotic plaques include
VSMCs, leukocytes, and ECs. Rekhter and Gordon78 demonstrated
divergence in the proliferation rates of these different cell types in
advanced atheromas from human carotid arteries. While mono-
cyte/macrophages are the predominant proliferative cell type in
the intima (46% monocyte/macrophages, vs. 9.7% a-actin immuno-
reactive VSMCs, 14.3% ECs, and 13.1% T-lymphocytes), proliferat-
ing VSMCs predominate in the media (44.4% VSMCs vs. 20% ECs,
13% monocyte/macrophages, and 14.3% T-lymphocytes). This
study also revealed higher proliferation rates in the intimal lesion
than in the underlying media (1.61+ 0.35 vs. 0.05+0.03%,
respectively), suggesting that different distributions of growth regu-
latory proteins and stimuli exist in different regions of human
atherosclerotic arteries.
4.2 Expression and localization of cell
cycle regulators in human atherosclerosis
As mentioned earlier, studies in animal models have demonstrated
both atheroprotective and atherogenic actions for different cell
cycle regulators. Human studies have demonstrated differential
expression of these proteins in atherosclerotic lesions and
healthy vessels,79– 81,85 – 89 thus highlighting the role of cell cycle
regulators in atherosclerosis development.
Quantitative immunoblotting analyses have demonstrated low
p27Kip1 levels in human atherosclerotic and restenotic coronary
arteries compared with aorta, internal mammary artery, and
carotid artery thrombendarterectomy specimens.85 In the same
study, p21Cip1 was found to be upregulated in restenotic lesions
compared with primary lesions and other vascular vessels. In
another report, Tanner et al.79 analysed CKI expression in
healthy and atherosclerotic specimens of human coronary artery.
Expression of p27Kip1 was abundant in non-proliferating cells
within normal and atherosclerotic arteries, whereas p21Cip1 was
undetectable in normal arteries but markedly upregulated in ather-
osclerotic tissue. Moreover, p27Kip1 and p21Cip1 expression was
most frequently found in non-proliferating regions within the
atheroma, suggesting an inverse correlation between arterial cell
proliferation and CKI expression. Interestingly, p27Kip1 and
TGF-b receptors are co-expressed in human atherosclerotic cor-
onary artery specimens, suggesting that the anti-mitogenic action
of TGF-b in these lesions might be mediated by p27Kip1.86
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The transcriptional regulator p53 is overexpressed, but not
mutated in human atherosclerotic tissue.89 Moreover, Ihling
et al.87 reported that p53 and p21Cip1 are co-expressed in non-
proliferating regions within advanced human carotid atherosclero-
tic plaques, thus indicating that p53-dependent transcriptional acti-
vation of p21Cip1 might protect against excessive vascular cell
growth. The same group reported p53 expression in apoptotic
cells within human atherosclerotic plaques.88 Moreover, p53 and
MDM2, a nuclear protein which promotes p53 degradation,
co-localize in a few Ki67-positive cells, suggesting that the
p53-dependent apoptosis or re-entry into the cell cycle might
depend on the relative abundance of these two proteins.
In addition to their roles as inhibitors of cell proliferation,
p16Ink4a, p21Cip1, and p53 might also play an important role in cel-
lular senescence, a process relevant to advanced atherosclerosis.90
Recent studies have revealed increased expression of p16Ink4a and
p21Cip1 in human coronary plaques, co-localizing with the activity
of the senescence marker b-galactosidase (SAbG).91 Interestingly,
cells from atherosclerotic lesions contain shorter telomeres,91
another characteristic linked to cell senescence and cardiovascular
disease.92 Marfella et al.93 also found that the expression of p16Ink4a
and p53 is markedly upegulated in atheromas from elderly patients
compared with younger patients undergoing carotid
endarterectomy.
4.3 Expression of cell cycle regulators
in human graft atherosclerosis
As discussed earlier, animal studies highlight the role of the
p53-p21Cip1 pathway in the pathophysiology of graft atherosclero-
sis. There is also evidence of p53 and p21Cip1 upregulation in
human graft atherosclerosis. McLaren et al.94 found elevated
expression of p53 in cardiac allograft recipients with acute rejec-
tion, and suggested this oncosuppressor as a potential myocyte
damage marker for the diagnosis of acute cardiac allograft rejec-
tion. Similarly, high levels of p53 were observed in atherosclerotic
areas of human aorto-coronary saphenous vein bypass grafts, with
a strong correlation between p53 expression and apoptosis (as
determined by TUNEL staining) in the intima, but not in the
media of vein grafts.95 In contrast to these findings, Baas et al.96
found almost undetectable p53 expression in coronary arteries
from transplanted hearts, although its transcriptional target
p21Cip1 was highly expressed.
5. Genetic evidence for the role of
cell cycle regulators in human
atherosclerosis
It is now widely accepted that the classic environmental risk factors
only partly explain the development of atherosclerosis, and that
genetic risk factors are critically involved in this pathology and its
clinical manifestations. Genetic polymorphisms associated with
atherosclerosis usually affect endothelial function, inflammation,
lipid metabolism, or the thrombosis and fibrinolysis cascades.
However, recent genetic studies have found robust genetic poly-
morphisms in genes involved in cell cycle regulation (mostly
CKIs), underlining the important role of cell proliferation in
atherogenesis.
5.1 The 9p21 genetic polymorphisms
and the INK4/ARF locus
The strongest and most replicated susceptibility locus for CAD and
MI so far identified in humans is located on chromosome 9p21, and
comprises several single nucleotide polymorphisms (SNPs) that
have been consistently associated with these diseases in several
independent Caucasian and Asian populations97– 103 (and others,
reviewed in104), but not in African American subjects.97,105 This
susceptibility locus is also associated with other vascular diseases,
such as abdominal aortic and intracranial aneurysms.106 The most
replicated 9p21 SNPs associated with CAD and MI lie in a region
100 Kb centromeric to the INK4/ARF locus, thus suggesting a link
between this locus and atherogenesis. The INK4/ARF locus plays
essential roles in cell proliferation, apoptosis, and senescence,
and encodes two CKIs (p15Ink4b and p16Ink4a), the p53-regulatory
protein ARF, and a recently discovered non-coding RNA named
ANRIL (for antisense noncoding RNA in the INK4 locus). Strik-
ingly, expression of all INK4/ARF transcripts is reduced in the per-
ipheral blood T-cells of individuals homozygotic for a common
9p21 SNP associated with increased risk of atherosclerosis
(rs10757278).107 This provides a direct link between these
atherosclerosis-associated SNPs and the INK4/ARF locus and
suggests a key role for p15Ink4b, p16Ink4a, ARF, and ANRIL in pro-
tecting against atherosclerosis development. Studies with geneti-
cally modified mice are warranted to assess whether INK4/ARF
gene products indeed affect atherogenesis.
5.2 Genetic polymorphisms in CKIs
of the Cip/Kip family
Several genetic studies have identified MI-associated variants in
human genes encoding CKIs of the Cip/Kip family. For example,
CDKN1C, the gene encoding p57Kip2, contains two polymorph-
isms (a promoter GT-repeat and a variable number of repeats of
the amino acid PAPA-motif) that were found to be associated
with MI.108 Similarly, the 2838C. A SNP within the CKDKN1B
gene (encoding p27Kip1) was found to be associated with increased
risk of MI and with reduced basal p27Kip1 promoter activity in pro-
liferating human cells.109 However, this SNP has also recently been
reported to confer a decreased risk of in-stent restenosis and a
20-fold increase in basal p27Kip1 promoter activity in quiescent
human cells.110 This apparent discrepancy, between decreased
risk of in-stent restenosis and increased risk of MI, might be
explained by the divergent pathophysiological roles of VSMCs in
restenotic and atherosclerotic lesions. In in-stent restenosis,
decreased VSMC proliferation can reduce neointima formation,
but in atherosclerotic plaques it can also diminish fibrous cap thick-
ness, increasing plaque vulnerability and potentially accounting for
the increased risk of MI. Regarding the divergent effects of this SNP
on p27Kip1 promoter activity, it should be noted that this activity
was assayed in different cell types (Jurkat vs. HEK293 cells) and
in different culture conditions (proliferating vs. quiescent cells).
Further studies are therefore required to conclusively define the
consequences of the -838C. A SNP on p27Kip1 expression.
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Moreover, larger cohorts need to be analysed to validate these
genotype-disease associations.
6. Concluding remarks
Mounting evidence demonstrates that excessive cell proliferation is
an essential hallmark of atherosclerosis development, both in
animal models and in human beings. Therefore, proteins involved
in the regulation of cell proliferation in the vascular wall are receiv-
ing special attention as potential therapeutic targets for the treat-
ment of vascular diseases. Studies in genetically engineered mice
have conclusively demonstrated the atheroprotective properties
of the growth suppressors p53, p27Kip1, and Rb and the surprising
proatherogenic function of p21Cip1, despite its well-defined cyto-
static activity. Interestingly, apart from their roles in regulating
cell proliferation, these proteins also appear to modulate other
cellular processes within the atheroma, such as apoptosis and
cell senescence. Further animal studies are warranted to analyse
the role of other cell cycle regulators in the development of ather-
osclerosis, especially in light of the genetic evidence suggesting
important roles for CKIs and ARF in the development of CAD
and MI in humans.
Although the evidence is conclusive that altering the cell cycle
machinery affects atherosclerosis development in animal models,
we are unaware of clinical trials targeting cell cycle regulators for
the treatment of native atherosclerosis. However, given that
administration of rapamycin (sirolimus) alleviates atherosclerosis
in the mouse (reviewed in111), prospective long-term trials
should be instigated to assess whether renal and heart transplant
recipients treated with this immunosuppressive and antiprolifera-
tive drug exhibit a reduction in morbidity and mortality attributable
to cardiovascular disease. In the case of graft atherosclerosis,
results obtained from animal studies have already been translated
into therapeutic strategies, although so far these have proved to
be unsuccessful in humans. Therefore, as our knowledge of the
role of cell cycle regulators in atherosclerosis grows, the challenge
will be to translate all this information into valuable diagnostic and
therapeutic tools for humans, as has been achieved in the setting of
post-angioplasty restenosis with the use of stents engineered to
deliver cytostatic drugs.
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